Fan Yang1,2, Ye Hu1,3, Ling Shao1, Jialang Zhuang1, Qin Huo1, Shengnan He1, Siqi Chen1, Juan Wang1, Ni Xie4. 1. Biobank, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, 518035, People's Republic of China. 2. Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo Institute of Life and Health Industry, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, People's Republic of China. 3. Department of Blood Purification Center, Affiliated Hengyang Hospital, Southern Medical University (Hengyang Centeral Hospital), Hengyang, Hunan, People's Republic of China. 4. Biobank, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, 518035, People's Republic of China. xn100@szu.edu.cn.
Abstract
PURPOSE: Emerging evidence suggests that cytotoxic therapy may promote drug resistance and metastasis while inhibiting the growth of primary tumors. As yet, however, the underlying mechanisms remain unclear. Here, we aimed to investigate the pro-metastatic effects of adriamycin (ADR) therapy on breast cancer cells and to investigate the mechanisms underlying these effects. METHODS: Differentially expressed genes between MCF-7 and ADR-resistant MCF-7 breast cancer cells were identified using high-throughput RNA-seq and differential gene expression analyses. In vitro transwell and scratch wound-healing assays, and an in vivo spontaneous metastasis model were used to study the metastatic potential of the breast cancer cells. The relationship between SIRT7 and TEK expression was studied using promoter activity, electrophoretic mobility shift (EMSA), CHIP-qPCR and Co-IP assays. RESULTS: Using transcriptome sequencing, we identified two key genes (SIRT7 and TEK) that might contribute to the pro-metastatic effect of ADR on breast cancer cells. SIRT7 acted as a negative regulator for TEK by inducing deacetylation of H3K18 at the TEK promoter. Through transcription factor prediction and double fluorescence experiments, we found that EST-1 could bind to the TEK promoter. Knockdown of EST-1 removed the transcriptional inhibition of TEK that was mediated by up-regulation of SIRT7. Co-IP showed that SIRT7 interacts directly with EST-1 in breast cancer cells, indicating that SIRT7 may induce H3K18 deacetylation at the TEK promoter region by directly binding to EST-1. In vitro and in vivo results showed that overexpression of SIRT7 or inhibition of TIE2 significantly reduced ADR-dependent breast cancer cell invasion/metastasis. CONCLUSION: Our findings suggest that ADR therapy may accelerate breast cancer metastasis in a SIRT7/TEK(TIE2) dependent manner.
PURPOSE: Emerging evidence suggests that cytotoxic therapy may promote drug resistance and metastasis while inhibiting the growth of primary tumors. As yet, however, the underlying mechanisms remain unclear. Here, we aimed to investigate the pro-metastatic effects of adriamycin (ADR) therapy on breast cancer cells and to investigate the mechanisms underlying these effects. METHODS: Differentially expressed genes between MCF-7 and ADR-resistant MCF-7 breast cancer cells were identified using high-throughput RNA-seq and differential gene expression analyses. In vitro transwell and scratch wound-healing assays, and an in vivo spontaneous metastasis model were used to study the metastatic potential of the breast cancer cells. The relationship between SIRT7 and TEK expression was studied using promoter activity, electrophoretic mobility shift (EMSA), CHIP-qPCR and Co-IP assays. RESULTS: Using transcriptome sequencing, we identified two key genes (SIRT7 and TEK) that might contribute to the pro-metastatic effect of ADR on breast cancer cells. SIRT7 acted as a negative regulator for TEK by inducing deacetylation of H3K18 at the TEK promoter. Through transcription factor prediction and double fluorescence experiments, we found that EST-1 could bind to the TEK promoter. Knockdown of EST-1 removed the transcriptional inhibition of TEK that was mediated by up-regulation of SIRT7. Co-IP showed that SIRT7 interacts directly with EST-1 in breast cancer cells, indicating that SIRT7 may induce H3K18 deacetylation at the TEK promoter region by directly binding to EST-1. In vitro and in vivo results showed that overexpression of SIRT7 or inhibition of TIE2 significantly reduced ADR-dependent breast cancer cell invasion/metastasis. CONCLUSION: Our findings suggest that ADR therapy may accelerate breast cancer metastasis in a SIRT7/TEK(TIE2) dependent manner.
Authors: Lisa Volk-Draper; Kelly Hall; Caitlin Griggs; Sandeep Rajput; Pascaline Kohio; David DeNardo; Sophia Ran Journal: Cancer Res Date: 2014-10-01 Impact factor: 12.701
Authors: Laura G M Daenen; Jeanine M L Roodhart; Miranda van Amersfoort; Mantre Dehnad; Wijnand Roessingh; Laurien H Ulfman; Patrick W B Derksen; Emile E Voest Journal: Cancer Res Date: 2011-10-05 Impact factor: 12.701
Authors: Ioanna Keklikoglou; Chiara Cianciaruso; Esra Güç; Mario Leonardo Squadrito; Laura M Spring; Simon Tazzyman; Lore Lambein; Amanda Poissonnier; Gino B Ferraro; Caroline Baer; Antonino Cassará; Alan Guichard; M Luisa Iruela-Arispe; Claire E Lewis; Lisa M Coussens; Aditya Bardia; Rakesh K Jain; Jeffrey W Pollard; Michele De Palma Journal: Nat Cell Biol Date: 2018-12-31 Impact factor: 28.824
Authors: Hisham Mohammed; I Alasdair Russell; Rory Stark; Oscar M Rueda; Theresa E Hickey; Gerard A Tarulli; Aurelien A Serandour; Aurelien A A Serandour; Stephen N Birrell; Alejandra Bruna; Amel Saadi; Suraj Menon; James Hadfield; Michelle Pugh; Ganesh V Raj; Gordon D Brown; Clive D'Santos; Jessica L L Robinson; Grace Silva; Rosalind Launchbury; Charles M Perou; John Stingl; Carlos Caldas; Wayne D Tilley; Jason S Carroll Journal: Nature Date: 2015-07-08 Impact factor: 49.962